Zimmer Biomet (NYSE: ZBH) executive vests 2,785 RSUs into common stock

Rhea-AI Filing Summary

Zimmer Biomet Holdings executive Yi Sang reported an equity award vesting and conversion. On February 25, 2026, 2,785 restricted stock units were exercised and converted into 2,785 shares of common stock at a stated price of $0.00 per share.

Following these transactions, Yi Sang directly held 5,567 restricted stock units and 22,837 shares of common stock. According to the vesting schedule, one-third of the RSUs vested on February 25, 2026, with the remaining units vesting one-half on each of February 25, 2027 and February 25, 2028.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yi Sang

(Last) (First) (Middle)

345 E. MAIN STREET

(Street)

WARSAW IN 46580

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ZIMMER BIOMET HOLDINGS, INC. [ ZBH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Group President, Asia Pacific

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/25/2026		M		2,785	A	$0	22,837	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	02/25/2026		M			2,785	(1)	(1)	Common Stock	2,785	$0	5,567	D

Explanation of Responses:

1. One-third of the RSUs vested on February 25, 2026. The remaining RSUs vest one-half on each of February 25, 2027 and February 25, 2028.

	/s/ Matthew R. St. Louis, Attorney-in-Fact for Sang Yi (power of attorney previously filed)	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Yi Sang report in this Zimmer Biomet (ZBH) Form 4 filing?

Yi Sang reported the vesting and conversion of an equity award. On February 25, 2026, 2,785 restricted stock units were exercised and turned into 2,785 shares of Zimmer Biomet common stock, reflecting compensation rather than an open-market share purchase or sale.

How many Zimmer Biomet RSUs vested for Yi Sang on February 25, 2026?

On February 25, 2026, 2,785 restricted stock units vested for Yi Sang. These RSUs were exercised and converted into an equal number of Zimmer Biomet common shares, as part of a multi-year vesting schedule tied to his role as Group President, Asia Pacific.

What are Yi Sang’s Zimmer Biomet share and RSU holdings after this Form 4?

After the reported transactions, Yi Sang directly held 22,837 shares of Zimmer Biomet common stock and 5,567 restricted stock units. These positions reflect his accumulated equity-based compensation and will change as future RSU tranches vest or additional awards are granted.

What is the vesting schedule for Yi Sang’s Zimmer Biomet restricted stock units?

The RSUs vest over three years. One-third vested on February 25, 2026. The remaining RSUs vest in two equal installments, with one-half vesting on February 25, 2027 and the final half vesting on February 25, 2028, subject to continued service terms.

Did Yi Sang buy Zimmer Biomet (ZBH) shares on the open market in this Form 4?

No, the filing reflects an RSU exercise and conversion, not an open-market purchase. The 2,785 Zimmer Biomet shares came from vested restricted stock units at a stated price of $0.00 per share, consistent with stock-based compensation terms.

What transaction code appears in Yi Sang’s Zimmer Biomet Form 4 and what does it mean?

The Form 4 uses transaction code M, described as an exercise or conversion of a derivative security. This indicates restricted stock units were converted into common shares, highlighting equity award vesting rather than discretionary buying or selling in the public market.